



ESMO Advanced Course on Cholangiocarcinoma: Where are we going?

PROGRAMME

**ESMO
ADVANCED COURSE**

**BARCELONA SPAIN
13-14 NOVEMBER 2026**

CO-CHAIRS

Julien Edeline, France

Angela Lamarca, Spain

esmo.org



ESMO ADVANCED COURSE PROGRAMME

CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Barcelona, Spain
13-14 November 2026

CO-CHAIRS

Julien Edeline, France
Angela Lamarca, Spain

SPEAKERS

Chiara Braconi, United Kingdom
Bas Groot Koerkamp, Netherlands
Maeve Lowery, Ireland
Teresa Macarulla, Spain
David Malka, France
Lorenza Rimassa, Italy
Anna Saborowski, Germany
Gonzalo Sapisochin, Spain
Ana Vivancos, Spain

LEARNING OBJECTIVES

- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 13 November 2026

09:00-09:10 **Welcome and introduction**

- 10' Welcome and learning objectives
Julien Edeline, FR and Angela Lamarca, ES

09:10-10:25 **Session 1 – Understanding biliary tract tumours**

Chair: Julien Edeline, FR

- 15' What are biliary tract tumours (primary site, epidemiology, and symptoms management)?
Teresa Macarulla, ES
- 15' Definitions of resectability
Gonzalo Sapisochin, ES
- 15' The role of pathology and molecular testing
Ana Vivancos, ES
- 10' Molecular testing algorithm
Angela Lamarca, ES
- 20' Discussion

10:25-10:55 Coffee break

10:55-12:00 **Session 2 – Locoregional and surgical therapies**

Chair: Angela Lamarca, ES

- 20' Locoregional therapy: Is it ready for the clinic?
Julien Edeline, FR
- 25' Biliary drainage, surgery and transplant
Bas Groot Koerkamp, NL
- 20' Discussion

12:00-12:50 **Session 3 – Adjuvant and neoadjuvant treatment**

Chair: Angela Lamarca, ES

- 30' Adjuvant and neoadjuvant treatment
David Malka, FR
- 20' Discussion

12:50-13:50 Lunch

13:50-14:50 **Session 4 – The management of advanced disease: Chemotherapy and immunotherapy**

Chair: Julien Edeline, FR

- 20' Chemotherapy - First line and second line: How is the field moving forward?
Angela Lamarca, ES
- 20' Immunotherapy: Rationale, current data, and upcoming studies
Lorenza Rimassa, IT
- 20' Discussion

14:50-15:50 **Session 5 – The management of advanced disease: Targeted therapies and new treatment options**

Chair: Julien Edeline, FR

- 20' Targeted therapies FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development
Maeve Lowery, IE

20'	Targeted therapies beyond FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development Anna Saborowski, DE
20'	Discussion
15:50-16:20	<i>Coffee break</i>
16:20-17:45	Session 6 – Bringing the latest science into patients care Chair: Angela Lamarca, ES
15'	Achieving best care options: Ongoing clinical trials, values of addressing to a phase I unit, and the role of centers of expertise Teresa Macarulla, ES
15'	The importance of translational research in trials and SoC practice: Biobanking and potential use of samples Chiara Braconi, UK
40'	Molecular tumor board Chiara Braconi, UK and Faculty
15'	Discussion
20:00	<i>Networking dinner</i>

Saturday, 14 November 2026

09:00-09:45	MDT case discussion Julien Edeline						
09:45-12:30	Workshop sessions Three parallel workshop sessions with 20 delegates in each group (Delegates will attend all 3 sessions on a rotational basis) <table> <tr> <td>10'</td><td>Introduction based on clinical cases presented by speakers</td></tr> <tr> <td>30'</td><td>Discussion</td></tr> <tr> <td>5'</td><td>Break</td></tr> </table> Workshop 1 Locoregional disease Julien Edeline, FR and Bas Groot Koerkamp, NL Workshop 2 Palliative chemotherapy (+/- immunotherapy) Angela Lamarca, ES and David Malka, FR Workshop 3 Molecular testing and targeted therapy Maeve Lowery, IE and Anna Saborowski, DE	10'	Introduction based on clinical cases presented by speakers	30'	Discussion	5'	Break
10'	Introduction based on clinical cases presented by speakers						
30'	Discussion						
5'	Break						
10:30-11:00	<i>Coffee break</i>						
11:00-12:30	Workshops continuation						
12:30-13:00	Feedback on the workshops from each group						
13:00-13:15	Synthesis and wrap-up Julien Edeline, FR and Angela Lamarca, ES						
13:15-14:15	<i>Lunch</i>						